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Hepcidin
Anil K. Agarwal and Jerry Yee
Dysregulation of metabolism and utilization of iron can lead to the development and maintenance of anemia of CKD. Anemia is
prevalent among patients with CKD. The markers of iron sufficiency or availability of iron are far from perfect which results in
inaccurate diagnosis and treatment of anemia with poor outcomes. Hepcidin, a 25 amino acid peptide produced by the hepatocytes, has emerged as the key regulator of uptake and release of iron in the tissues to maintain a steady supply of iron to erythron and other tissues while avoiding higher levels of iron that could be detrimental to the organs. Hepcidin itself is regulated
by the supply of iron, the need for erythropoiesis, and the state of inflammation. Alterations in hepcidin levels are associated
with restricted erythropoiesis, anemia, and iron overload. Discovery of hepcidin and elucidation of its mechanism of action
and consequences of its upregulation and suppression have unraveled important insight into many hematologic disorders
including anemia of CKD. This knowledge has also unlocked unique opportunities to modulate hepcidin via agonists and antagonists of hepcidin and its feedback pathways to treat clinical conditions. Many such agents are being developed and have potential therapeutic utility in future.
Q 2019 by the National Kidney Foundation, Inc. All rights reserved.
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A

n adequate amount of iron is essential for many molecular processes including energy production as
well as heme formation to facilitate oxygen delivery to
the tissues. An excessive amount of iron, however, can
be detrimental through the formation of reactive oxygen
species with resultant oxidative stress, damage to DNA,
and potentiation of lipid peroxidation and ferroptosis of
cells. Even in the presence of adequate iron stores, a maldistribution of iron can result in anemia as in inﬂammation
and chronic disease such as CKD. As iron losses are relatively constant and not regulated, the absorption and
release of iron from cells is regulated through a multitude
of proteins to carefully maintain intracellular and systemic
levels of iron that are both adequate and safe.

HEPCIDIN PRODUCTION, ACTION, AND
REGULATION
Hepcidin was discovered as the liver-expressed antimicrobial peptide in 2000.1,2 Hepcidin is produced primarily by
the hepatocytes which are strategically located in the
vicinity of portal veins (carrying dietary iron) as well as
the Kupffer cells (sensing microbes and recycling
erythrocytes).3 Hepcidin is also produced by macrophages
and adipocytes in a small quantity.4,5
Hepcidin is encoded by the hepcidin antimicrobial peptide (HAMP) gene. It is initially synthesized as an 84 amino
acid pre-pro-hepcidin. It is then processed to 60 amino acid
pro-hepcidin and ultimately sliced to a mature C-terminal
25 amino acid active peptide.6 Hepcidin is a tightly folded
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peptide hormone that forms a simple hairpin structure stabilized by 4 disulﬁde bonds (Fig 1).7 Mutations of the
HAMP gene are associated with severe iron overload
and hemochromatosis. Hepcidin expression is increased
in iron overload and inﬂammation and is diminished in
states of iron deﬁciency and hypoxia.8
Hepcidin transcription is regulated by bone morphogenic protein (BMP) and its coreceptor hemojuvelin
(HJV) in the liver. A number of BMPs, speciﬁcally
BMP-6, can induce HAMP expression and upregulate
hepatocyte hepcidin expression, a process enhanced
by HJV and blunted in hemojuvelin knockout (Hfe22/2)
hepatocytes.9 BMPs bind to type I and type II receptors
leading to signal transduction. BMP and transforming
growth factor-beta induce hepcidin expression via
“small” worm phenotype and Mothers Against Decapentaplegic (SMAD) signaling.10 HJV is a member of the
repulsive guidance molecule family and acts as a BMP
coreceptor. HJV gene (also known as HFE2) mutations
can result in hepcidin deﬁciency and juvenile hemochromatosis.11 A number of other pathways and compounds
partake in hepcidin regulation in a complex manner.3
Hepcidin gene expression is upregulated by inﬂammation and iron through the Janus kinase/signal transducers and activators of transcription (JAK/STAT) and
BMP/SMAD pathways, respectively.6 The BMP-6 signal
acts through its receptor (BMPR), and is modulated by
HJV. The TMPRSS6 (transmembrane serine protease-2)
gene encodes matriptase-2 (MT2) which cleaves
membrane-bound HJV. BMPs can also signal through
SMAD-independent pathways, notably via mitogenactivated protein (MAP) kinases. Dorsomorphin inhibits
BMP signaling through the SMAD pathway. SMAD
complexes bind to BMP-responsive elements. Tumor necrosis factor (TNF), pathogens, and interleukin-6 (IL-6)
stimulate hepcidin synthesis via signal transducer and
activator of transcription 3 (STAT-3) activation. The P38
MAP-kinase and extracellular signal-regulated kinases
(ERK) 1-2 pathways are activated in response to iron signals. Diferric transferrin (Tf) binds to TF-receptor 1 (TfR1) on the cell surface and the complex undergoes
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endocytosis. HFE is a protein that competes with Tf for
Hepcidin levels decrease in hypoxia, although the exact
binding to TfR-1. Hepcidin expression in macrophages is
mechanism is unclear. Hypoxia inducible factor may supregulated mainly through TLR4 receptors associated
press hepcidin transcription directly or through activation
with adaptor proteins. Hepcidin mRNA expression in
of furin to release soluble HJV which interferes with BMP
macrophages induced by lipopolysaccharide (LPS) or
signaling and leads to inhibition of hepcidin activahigh mobility group protein B1 (HMGB1) depends on
tion.15,16 Hepcidin synthesis is increased during periods
of infection or inﬂammation. The hepatocyte production
nuclear factor kappa-light-chain-enhancer of activated
of hepcidin in such states is regulated by IL-6 through
B cells (NFkB).
the STAT-3 signaling pathway.
Vitamin D is a potent negative regulator of hepcidin
transcription in cultured monocytes and hepatocytes
HEPCIDIN IN IRON REGULATION AND
and also induces antibacterial proteins such as catheliciERYTHROPOIESIS
din.12 In an in vivo and in vitro study, seven healthy volunteers received a single oral dose of vitamin D (100,000
It is important to understand iron metabolism in orIU vitamin D2) which increased serum levels of 25-hyder to understand therapeutic modulation of hepcidin.
droxyvitamin D from 27 6 2 ng/mL before supplementaTotal body iron stores are approximately 4 g with
tion to 44 6 3 ng/mL after supplementation (P , .001).
daily iron losses of 1-2 mg, which must be replenished
This response was associated with a 34% decrease in
via the absorption of dietary iron. Erythropoiesis recirculating levels of hepcidin within 24 hours of vitamin
quires 20-25 mg of iron daily, most of it coming
D supplementation. The high levels of hepcidin in pafrom recycling by erythrophagocytosis of senescent
tients with CKD may
red cells. Daily requirement
possibly be due not only
of dietary iron differs
CLINICAL SUMMARY
to reduced renal excretion
among individuals accordof hepcidin but also to
ing to their age and gender,
vitamin
D
deﬁciency,
especially in young females
 Hepcidin, produced by hepatocytes, is the key regulator of
uptake and release of iron in tissues; hepcidin is regulated
which is widely prevalent
due to a much larger iron
by iron supply, erythropoietic requirements, and
in this population.
loss during menstruation.
inflammatory status.
Hepcidin 25 has both iron
Iron absorption and availregulatory and antimicroability in the plasma are
 Changes in hepcidin concentrations are associated with
bial activities, but hepcidin
regulated by hepcidin.
iron-restricted erythropoiesis, anemia, and iron overload.
22 and 20 have only antimiIron uptake is mediated by
 Hepcidin levels exhibit biological variation and subject to
crobial activity. Hepcidin 25
the H1 coupled Fe21 transalterations in renal excretion and inflammation, thereby
porter known as divalent
binds to ferroportin, a transrendering hepcidin an unsuitable biomarker of iron status
membrane protein, and
cation transporter 1/divalent
or predictor of ESA-responsiveness.
leads to its degradation
metal ion transporter 1
 Modulation of the hepcidin-ferroportin axis by agonists/
(DMT1) at the brush border
and consequent inhibition
antagonists represents an attractive future target for
of iron release from enteroof the duodenal enterocytes.17
novel preventive or therapeutic strategies for disorders of
cytes, macrophages, and
This is facilitated by the
iron metabolism and erythropoiesis.
hepatocytes to regulate
membrane
ferrireductase,
iron absorption and utilizaduodenal cytochrome B. Iron
tion. Hepcidin is cleared
enters via enterocytes, is
via its internalization and degradation with ferroportin
stored in the hepatocyte cytoplasm and macrophages,
and must exit the cell on demand. The exit of the reduced
as well as through its excretion by the kidneys. Although
hepcidin controls iron transport, its production is reguiron from the cell requires the presence of ferroportin, a
lated by the systemic availability of iron, erythropoietic
transmembrane protein, which is the only way for iron
to exit into the blood. Hepcidin-ferroportin axis is an interequirement, as well as by the state of inﬂammation (Fig
2).3
gral mechanism regulating the export of iron from the
Hepcidin production is impacted by the feedback loop of
cells. The iron is again oxidized by the membrane bound
systemic availability of iron. Hepcidin is produced in the
ferroxidase hephaestin and ceruloplasmin and is then
iron-rich environment (whether in plasma or in tissues)
taken up by Tf. Tf releases iron to the cells by binding priand its production is reduced or stopped when iron is deﬁmarily to the TfR-1 on the cell membrane which stimulates
cient or in high demand. In the presence of active erythroits endocytosis and transport to mitochondria for heme
poiesis, production of hepcidin is inhibited, at least
synthesis or to cytoplasm to be stored as ferritin. Lack of
partially via an erythroid factor (erythroferrone, ERFE)
ferroportin would render intracytoplasmic iron to be trapproduced by the erythroblasts that suppresses the BMP/
ped within the cell. Thus, ferroportin degradation by hepSMAD pathway in the liver. In vitro, ERFE decrease
cidin leads to inhibition of the transport of iron out of the
SMAD1, SMAD5, and SMAD8 phosphorylation and induodenal enterocytes and a blockade of iron release
hibits expression of BMP target genes, suppressing the infrom the macrophages and hepatocytes resulting in iron
duction of hepcidin by BMP5, BMP6, and BMP7 without
sequestration and depletion of the blood pool of iron. Cells
affecting hepcidin induction by BMP2, BMP4, BMP9, or acthat have intracellular iron but lack ferroportin have to be
tivin B.13,14
recycled upon cell death by macrophages.
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Figure 1. Two distinct conformations of hepcidin resolved at
high and low temperature. A, high temperature nuclear
magnetic resonance (NMR) ensembles; B, low temperature
NMR ensembles. Adapted with permission from Jordan et
al7; Ó 2009 by The American Society for Biochemistry and
Molecular Biology, Inc.

Coordination and balance between iron uptake at the
brush border and its exit from the basolateral membrane
is tightly regulated. This involves a complex relationship
between cellular iron accumulation, leading to activation
of hepcidin with its effect on iron-binding proteins, and
decreased formation of DMT1, degradation of hypoxia
inducible factor, and activation of transubiquitination of
DMT1.17-19
Iron overload induces the formation of BMPs by the hepatic sinusoidal endothelial cells. BMPs activate phosphorylation of Smad1/5/8 phosphorylation, which forms a
transcriptional activator complex with Smad4 to stimulate
hepcidin transcription.20 HJV or HFE2, a membrane bound
GPI-anchored protein, acts as a BMP coreceptor and promotes hepcidin transcription.9 A soluble form of HJV
(sHJV) blocks BMP-6 and inhibits hepcidin expression.21
HJV is cleaved by matriptase 2 (MT2), and BMP receptor,
HJV, and MT2 are stabilized by neogenin.22
Degradation of ferroportin by hepcidin requires direct
binding of hepcidin to its receptor ferroportin.23 The binding depends upon the presence of amino acid cysteine in
position 326 on the extracellular loop of ferroportin.
Absence of this amino acid in this position, as in the variant
ferroportin, renders hepcidin unable to bind to ferroportin
and can result in iron overload. The hepcidin-ferroportin
complex then undergoes a conformational change leading
to its endocytosis and lysosomal degradation. Studies of
hepcidin structure also reveal that the ﬁrst 9 N-terminal
amino acids can internalize ferroportin—a conformational
concept known as mini-hepcidin.24
HEPCIDIN IN HOST DEFENSE AND INFECTION AND
ANEMIA OF INFLAMMATION
Growth and pathogenicity of many microbes require presence of iron.25 Reduction in extracellular iron concentration
has evolved over time as a host defense mechanism against
infection. Protein-bound iron, as in ferritin, Tf, lactoferrin,
or ovotransferrin, is not readily available for uptake by
the microbes. Through ferroportin degradation, hepcidin
decreases blood iron level to defend against infection.
Inﬂammation and infection result in increased production of IL-6 and TNF-alpha. IL-6 directly regulates hepcidin production through induction and subsequent
promoter binding of STAT-3.26 STAT-3 is not only necessary but also sufﬁcient for the IL-6 responsiveness of the
hepcidin promoter. STAT-3 signaling is inﬂuenced by
BMP-dependent Smad activation.10 An increase in hepcidin reduces iron concentrations in the blood which might

Figure 2. Hepcidin has a central role in maintenance of iron
homeostasis. Hepcidin synthesis is regulated at the transcriptional level by multiple stimuli. Intracellular and extracellular iron concentrations increase hepcidin transcription,
as does inflammation, whereas increased erythropoietic
activity suppresses hepcidin production. In turn, hepcidin
regulates plasma iron concentrations by controlling ferroportin concentrations on iron exporting cells including
duodenal enterocytes, recycling macrophages of the spleen
and liver, and hepatocytes. Adapted and reprinted from Ganz
and Nemeth,3 with permission from Elsevier.

be helpful in defense against iron-dependent microbes.
However, this very action of hepcidin forms the basis
of iron sequestration and anemia of inﬂammation. Inﬂammatory conditions may be associated with other hepcidin
independent mechanisms such as decreased red cell
survival and bone marrow suppression that contribute
to anemia.
CLINICAL IMPLICATIONS
Dysregulation of hepcidin (HAMP) or related genes such
as hemochromatosis (HFE), transferrin receptor 2 (TFR2),
and HJV and conditions such as beta-thalassemia intermedia are known to result in states of dysregulated ferroportin. These conditions are often associated with increased
iron absorption as well as export, resulting in excessive
amounts of free systemic iron and excessive iron uptake
by the tissues with consequent tissue damage. Insufﬁcient
production of hepcidin mediated by the mutations in hepcidin or HJV gene is associated with iron accumulation as
in hereditary hemochromatosis. Beta-thalassemia, characterized by defective beta globin production and ineffective
erythropoiesis, is also associated with hyperabsorption of
dietary iron, which is linked to the presence of hepcidin
suppressors such as ERFE. Hepcidin suppression is
also mediated by the growth differentiation factor 15
(GDF15), a member of the transforming growth factor
beta superfamily.27 The twisted gastrulation protein homolog 1 TWSG1 also interferes with BMP 2 and 4mediated hepcidin expression and may act with GDF15
to dysregulate iron homeostasis in thalassemia syndromes.28 Therapy with hepcidin agonists may in future
become a potential therapy for iron overload disorders.
Hepcidin circulates in blood in a protein-bound form,
but with low afﬁnity, leading to the presence of free hepcidin which is ﬁltered by the kidney and degraded in
Adv Chronic Kidney Dis. 2019;26(4):298-305
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Table 1. Hepcidin Levels in Health and Disease
Serum hepcidin level
Gender
Diurnal variation
Disease states

Low

High

Women
Morning
Iron deficiency, beta thalassemia intermedia, juvenile
hereditary hemochromatosis

Men
Afternoon
Secondary iron overload (such as iron transfusions),
iron refractory iron deficiency anemia, adult
hereditary hemochromatosis (though
inappropriately low for the degree of iron
overload), inflammation, infection, cancers such as
multiple myeloma, and Hodgkin’s disease

proximal tubule. Hepcidin levels in plasma are signiﬁcantly elevated in patients on hemodialysis and can aggravate iron sequestration. Hepcidin levels decrease
signiﬁcantly after hemodialysis.29 The improvement in
anemia management in patients on prolonged dialysis
may be partly related to hepcidin clearance.30
On the other end of the spectrum, hepcidin overexpression can result in iron restrictive anemia as in the case of
hepcidin-expressing hepatic adenomas or in familial iron
refractory iron deﬁciency anemia due to the mutations in
MT2 which is an inhibitory regulator of hepcidin. Ferroportin deﬁciency due to missense mutations can also
lead to impaired export of iron from cells and lead to
iron restricted erythropoiesis. Anemia of some malignancies can also be related to hepcidin overproduction.
Local levels of BMP are more important than the systemic
level in these circumstances.
ANEMIA OF CKD AND HEPCIDIN AS A BIOMARKER
Anemia of CKD is characterized by inappropriately
decreased production of erythropoietin by the kidneys
where erythropoietin levels are indeed elevated but not
commensurate with the severity of anemia. Anemia of
CKD is truly multifactorial, resulting from a relative erythropoietin deﬁciency compounded by the deﬁciency, loss,
sequestration, and poor utilization of iron with characteristics of anemia of inﬂammation. Interestingly, patients
with anemia of CKD do respond to the supraphysiologic
doses of erythropoiesis-stimulating agent (ESA) as well
as high-dose intravenous iron even in the presence of
adequate levels of iron.31 High serum levels of hepcidin
have been demonstrated in patients with kidney disease.
In a study of CKD patients, bioactive serum hepcidin using
a novel competitive ELISA was used to accurately measure
hepcidin.32 Hepcidin levels were signiﬁcantly elevated
compared with respective age controls as tested by analysis of variance. Additionally, each quartile of CKD patients had signiﬁcantly different hepcidin levels. In this
study, hepcidin levels were shown to be predicted by
ferritin, C-reactive protein, and stage of kidney disease.
A variety of laboratory tests have been used to assess iron
deﬁciency in patients with anemia. These include ferritin,
Tf saturation, percent of hypochromic red cells, and soluble TfR. However, current methods of assessing adequacy
of iron stores and iron availability to the erythron are
grossly inadequate, especially in the presence of inﬂammation, and are unable to guide the clinician to formulate

a strategy to treat anemia. Tf saturation, soluble TfR, and
ferritin levels do not provide accurate insight. The association of hepcidin levels with the stage of CKD and ferritin
and its inverse relationship with ESA therapy support the
possibility that hepcidin could be a biomarker of iron status.33 However, there is signiﬁcant intrapatient variability
in hepcidin level measurements. Additionally, hepcidin is
dependent on kidney function for its excretion, and the
levels increase with the presence of inﬂammation and
are not necessarily different in patients sensitive or resistant to ESA.34 Considering these factors along with nonharmonization of different hepcidin assays, the hepcidin
levels cannot be considered a biomarker of iron status or
a predictor of ESA response at this time.
HEPCIDIN ASSAYS
The availability, accuracy, interpretation, and clinical implications of hepcidin assays have been controversial.
One study tested 11 different assays (5 mass
spectrometry-based and 6 immunochemical-based) to
quantify native individual plasma samples (n ¼ 32) and
native plasma pools (n ¼ 8) to assess analytical performance and current and achievable equivalence.35 Absolute
hepcidin values and reproducibility (intrameasurement
procedure coefﬁcient of variation 2.9%–8.7%) differed substantially between measurement procedures, but all were
linear and correlated well. The current equivalence
(intermeasurement procedure coefﬁcient of variation
28.6%) between the methods was mainly attributable to
differences in calibration and thus could be improved by
harmonization with a common calibrator.
Antibody-based immunoassays and mass spectrometric
assays have been available to measure hepcidin, and measurements of bioactive serum hepcidin using a novel
competitive ELISA are now available and have shown clinical correlation. Due to the decreased hepcidin clearance in
the presence of kidney disease, serum measurements of
hepcidin might be more accurate than urinary hepcidin
measurements. It is important to remember that hepcidin
has a biological variation (women have a lower level of
hepcidin than men) and a diurnal variation (levels are
lower in the morning and higher in the afternoon)
(Table 1).
HEPCIDIN AS TARGET FOR THERAPY
Current treatment of anemia associated with dysregulated
iron metabolism comprises of a spectrum of therapies.
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These range from iron administration with and without
ESA for iron deﬁciency to chelation and phlebotomy for
iron overload. As hepcidin has a central role in iron regulation and a pathogenetic role in most clinical conditions
associated with anemia, there is a potential to modulate
hepcidin-ferroportin axis for treatment or prevention of
such conditions. A number of such approaches are in
development.36
Hepcidin Agonists
Hepcidin agonists may be able to prevent and treat iron
overload. Natural hepcidin is expensive and not suitable
for therapeutic use due to a short half-life and rapid renal
clearance. A minimal structure with 7-9 N-terminal amino
acids of hepcidin, including a single thiol cysteine, retains
hepcidin activity, as shown by the induction of ferroportin
degradation in reporter cells. This “mini-hepcidin” acts as
a hepcidin-mimetic and has been further modiﬁed to
improve its half-life and absorption. In mouse models,
mini-hepcidin has been shown to control iron overload.24,37 Such therapy may have potential use in
hereditary hemochromatosis and beta-thalassemia.
Apart from the hepcidin mimetics, there are other stimulators of hepcidin production. Soy-derived isoﬂavone genistein is a small molecule activator of the Stat/Smad
pathway that has been shown to enhance hepcidin expression in preclinical models.38 MT2 is a negative regulator of
hepcidin production and its inactivation can be useful in
iron overload disorders. Antisense oligonucleotides and
single stranded nucleic acids that lead to degradation of
their target mRNA, have been used to increase hepcidin
levels and decrease iron load in mouse models.39,40
Another approach involves use pf lipid nanoparticles
loaded with double-stranded small interfering RNAs (siRNAs) to inhibit the expression of its target genes through
RNA interference. Small-molecule inhibitors of MT2 increase hepcidin production by inhibiting cleavage of
HJV. In a mouse model this approach was used to deliver
the MT2 siRNA to the liver to block MT2 RNA translation;
similar to the antisense oligonucleotide approach, it was
effective in b-thalassemia and iron overload.41 These
agents may also be able to help treating siderophilic infections.
BMP6 has also been used in animal models to increase
hepcidin transcription and decrease serum iron.42 However, such an approach is compromised by the off-target actions of BMP6.
Hepcidin Antagonists
Inhibition of hepcidin activity can form the basis of treatment of anemia characterized by iron restriction, such as
anemia of inﬂammation and cancer. Hepcidin antagonism
can be approached in multiple ways that include direct inhibition of hepcidin, inhibition of hepcidin ferroportin
binding, inhibition of hepcidin-induced ubiquitination of
ferroportin, and endocytosis of ferroportin. Suppression
of inﬂammation can also indirectly suppress hepcidin
levels.
Direct hepcidin inhibition can be achieved via antibodies
to hepcidin, hepcidin-binding oligoribonucleotides, and

inhibitors of hepcidin expression. Hepcidin neutralizing
monoclonal antibodies have been shown to be effective
in anemia of inﬂammation in a mouse model.43 Hepcidin
neutralization with antibodies in AI mice substantially
improved iron-dependent red cell parameters. The use of
anti-hepcidin antibody along with ESA therapy was able
to correct anemia, although neither agent was effective
alone in inducing reticulocytosis, demonstrating synergy
between the 2 treatments. This ﬁnding suggests that by
improving effective hemoglobinization of progenitors,
hepcidin neutralization may have created permissive conditions to allow an effective reticulocyte response to erythropoietin. Hepcidin neutralization likely improves
distribution of iron and better dietary absorption of iron,
which might also reduce the requirements of parenteral
iron. A drawback of this approach is the high rate of production of hepcidin, although even a short-term suppression might be able to facilitate erythropoiesis.
Gene silencing using RNA interference is a common
technique to study gene function but can also be utilized
for therapeutic purposes. siRNAs have been developed
against the HAMP gene and other targets including HJV,
TFR2, HFE, neogenin, BMP6, BMPRI, BMPRII, SMAD4,
and IL-6R to further characterize the hepcidin signaling
pathway.44 Treatment with HAMP-targeting siRNA was
able to blunt hepcidin induction, hypoferremia, and the
onset of anemia in a turpentine-induced mouse model of
inﬂammatory anemia. Silencing other members of the hepcidin pathway resulted in decreased HAMP expression
and increased Tf saturation to varying degrees. A single
0.1 mg/kg dose of a TFR2-targeting siRNA resulted in
nearly 80% silencing of both TFR2 and HAMP and 100%
Tf saturation within 24 hours postadministration in mice.
In addition, TFR2 targeting resulted in the resolution of
anemia in rodent models of anemia of inﬂammation.
This mode of genetic manipulation may represent a novel
approach for the treatment of anemia of chronic disease
and anemia of CKD.
Spiegelmer technology utilizes L-enantiomeric oligonucleotides that can inhibit speciﬁc targets, such as hepcidin.
Spiegelmer NOX-H94 has been modiﬁed to NOX-H94002
and its PEGylated variant binds human hepcidin with
high afﬁnity to block its biological function. It has been
shown to counteract anemia of inﬂammation in cynomolgus monkeys.45 Antisense oligonucleotides to inhibit
translation of hepcidin or HJV are also in development.
Hepcidin suppression by ERFE may be the basis of anemia associated with ineffective erythropoiesis, and
neutralization of ERFE may be a potential therapy of
iron overload in such disorders. By suppressing hepcidin,
ERFE could be a potential treatment of iron-restrictive anemia characterized by increased hepcidin as in inﬂammation, CKD, and iron-refractory iron-deﬁciency anemia.
It is also possible to target ferroportin for amelioration of
hepcidin-induced iron restriction. Antibody to ferroportin
was effective in raising serum iron levels in a monkey
model.46 A thiol-reactive compound fursultiamine interferes with the binding of hepcidin to ferroportin.47 Fursultiamine acts in vitro by blocking ferroportin residue
Cys326-SH but has a short half-life in vivo. Targeting
Adv Chronic Kidney Dis. 2019;26(4):298-305
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ferroportin synthesis or its endocytosis is also being investigated. A shortcoming of hepcidin antagonists is a homeostatic feedback response with increased expression via
other pathways.
Many other pharmacologic compounds have antihepcidin activity. Some of these include cardiac glycosides,
thioxolone, and pyrithione zinc, in low doses. Some other
commonly used compounds such as vitamin C, vitamin A,
and statins have been implicated in hepcidin suppression.
MT2, a membrane-bound serine protease, inhibits hepcidin expression by depressing BMP/SMAD signaling. It is
mutated in iron refractory iron deﬁciency anemia leading
to high hepcidin levels. Small molecule ferroportin inhibitors and TMPRSS6 antisense nucleotides increase hepcidin
levels and reduce serum and liver levels of iron in preclinical models of hemochromatosis and thalassemia.
Anticalins are derivatives of lipocalins which are
involved in the transport of lipids and steroids into the
cell. Anticalin PRS-080 binds human hepcidin with subnanomolar afﬁnity and blocks the hepcidin-FPN receptor
interaction. A single 3 mg/kg intravenous bolus of PRS080 showed dose-dependent and hepcidin-speciﬁc iron
mobilization in cynomolgus monkeys.48
STAT-3 pathway is involved in hepcidin regulation and
small molecule STAT-3 inhibitors such as AG490 and the
synthetic peptide inhibitor of STAT-3 (PpYLKTK) abolish
hepcidin expression in mice. AG490 inhibits the phosphorylation of STAT-3 by JAK2, and the PpYLKTK disrupts
phospho-STAT-3 dimerization, which is required for binding target genes.49 Curcumin also inhibits STAT-3, can be
anti-inﬂammatory, and may have potential iron chelating
activity.50
Mediators of inﬂammation can also be targeted to reduce
hepcidin synthesis. Administration of tocilizumab, a humanized antibody to IL-6 receptor, reversed anemia in
cynomolgus monkeys by decreasing hepcidin production.51 Administration of tocilizumab to these arthritic
animals rapidly decreased CRP levels and improved
iron-deﬁcient anemia within 1 week. Tocilizumab induced
rapid but transient reduction in serum hepcidin-25. TNFalpha blockers etanercept, adalimumab, and inﬂiximab
have also been reported to ameliorate anemia in patients
with inﬂammatory arthritis, such as rheumatoid arthritis
and psoriasis, although this effect may be either indirect
via the suppression of IL-6 production or through a direct
effect on erythropoiesis.52 Etanercept is a soluble TNF
receptor fusion protein and maintains efﬁcacy longer as
compared to the anti-TNF-alpha antibodies due to the
absence of antidrug antibodies.
BMP pathway has been targeted to reduce hepcidin production. Humanized anti-BMP monoclonal antibody was
shown in healthy mice to block hepatic hepcidin production and increase serum iron.53 Small molecule dorsomorphin derivative LDN-193189 or the protein soluble
hemojuvelin-Fc inhibit BMP type I receptor Smadmediated signaling required for effective hepcidin
transcription. In a rat model of anemia of chronic
inﬂammation, LDN-193189 blocks endogenous hepcidin
production and results in mobilization of iron from the
reticuloendothelial system, stimulates erythropoiesis,
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and corrects anemia.54 Heparins bind to BMP but cannot
be used due to anticoagulant properties. Low molecular
weight heparin in the treatment of deep vein thrombosis
has shown a robust reduction in hepcidin levels. Nonanticoagulant heparins have been developed that interfere
with BMP/SMAD signaling.55 Alcohol can also inhibit
BMP receptor activation and signaling.56 As mentioned
above, the potential issues include inhibition of other
BMP-dependent pathways and a speciﬁc antagonist with
no off-target effects of BMP antagonism would be desirable.
Finally, recent developments in the area of hypoxiainducible factor prolyl hydroxylase inhibitor have shown
the capability to overcome hepcidin in the treatment of
anemia of kidney disease. These are being discussed elsewhere in this issue.
FUTURE DIRECTIONS
Iron is an essential nutrient regulated via multiple pathways and hepcidin has emerged as a central regulator of
iron homeostasis. Discovery of these pathways and understanding of the mechanisms of hepcidin action have
created an opportunity to intervene in many disease states
related to hepcidin under- or over-production. Development of speciﬁc molecules to target a speciﬁc step in the
hepcidin-ferroportin axis regulation has the potential to
develop individualized treatment of speciﬁc conditions.
These developments are providing further understanding
of the intricacies of hepcidin metabolism and therapeutic
developments will need to be speciﬁc to avoid unintended
consequences of hepcidin modulation.
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